Northwest Bio up 13% premarket

Shares of Northwest Biotherapeutics (NWBO) are poised for a strong up move at the open in response to its announcement that the Data Safety Monitoring Board recommends the continuation of its DCVax-L Phase 3 GBM trial.

The unblinded review was conducted in response to shareholder inquiries.

Prices have been on a roller coaster of late. In November, shares doubled, retraced, then shot up almost 150% to a February 27 peak of $7.92 before correcting. Shares closed yesterday at $5.96.

From other sites
Comments (2)
  • alext1379
    , contributor
    Comments (811) | Send Message
    Will this just jump for people to short while it fills the gap? Its teh way the markets have been working lately, MM pump, sell calls, then force price down to ensure calls expire and the premiums on this baby are quite nice.


    It doesn't implicitly say the Phase 3 was successful but only that they should continue, meaning it wasn't a failure but not a resounding success.


    I think I'll wait for pullback/gap fill to jump add more to my sub $5 stash.
    7 Mar 2014, 09:18 AM Reply Like
  • arikezia
    , contributor
    Comments (5) | Send Message
    You are obviously much more sophisticated than I. Would you mind emailing me to act as prof? I understand the companies; I only own biotech stock.
    (I am a retired pharmacist) but can't get an understanding of the movements you describe with abbreviated expressions. Thanks,
    9 Mar 2014, 05:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs